Strs Ohio Invests $919,000 in Protagonist Therapeutics, Inc. $PTGX

Strs Ohio bought a new position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 19,000 shares of the company's stock, valued at approximately $919,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. GF Fund Management CO. LTD. bought a new stake in shares of Protagonist Therapeutics in the 4th quarter worth about $48,000. GAMMA Investing LLC increased its position in shares of Protagonist Therapeutics by 153.3% in the 1st quarter. GAMMA Investing LLC now owns 1,203 shares of the company's stock worth $58,000 after purchasing an additional 728 shares during the last quarter. Smartleaf Asset Management LLC increased its position in shares of Protagonist Therapeutics by 141.7% in the 1st quarter. Smartleaf Asset Management LLC now owns 1,211 shares of the company's stock worth $59,000 after purchasing an additional 710 shares during the last quarter. Brooklyn Investment Group bought a new stake in shares of Protagonist Therapeutics in the 1st quarter worth about $68,000. Finally, PNC Financial Services Group Inc. increased its position in shares of Protagonist Therapeutics by 38.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 1,992 shares of the company's stock worth $96,000 after purchasing an additional 551 shares during the last quarter. Institutional investors own 98.63% of the company's stock.

Analyst Upgrades and Downgrades

PTGX has been the subject of a number of recent research reports. Wall Street Zen raised shares of Protagonist Therapeutics from a "sell" rating to a "hold" rating in a research report on Sunday, June 8th. Leerink Partners initiated coverage on shares of Protagonist Therapeutics in a research report on Friday, September 12th. They set an "outperform" rating and a $73.00 price objective for the company. Citigroup reaffirmed an "outperform" rating on shares of Protagonist Therapeutics in a research report on Thursday, August 7th. HC Wainwright reaffirmed a "buy" rating and set a $80.00 price objective on shares of Protagonist Therapeutics in a research report on Wednesday. Finally, Barclays initiated coverage on shares of Protagonist Therapeutics in a research report on Wednesday. They set an "overweight" rating and a $72.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $68.08.

Insider Transactions at Protagonist Therapeutics

In other Protagonist Therapeutics news, CEO Dinesh V. Ph D. Patel sold 22,065 shares of the business's stock in a transaction dated Tuesday, July 22nd. The shares were sold at an average price of $55.05, for a total transaction of $1,214,678.25. Following the completion of the transaction, the chief executive officer directly owned 548,538 shares of the company's stock, valued at $30,197,016.90. The trade was a 3.87% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director William D. Waddill sold 4,000 shares of the business's stock in a transaction dated Wednesday, August 27th. The shares were sold at an average price of $59.25, for a total transaction of $237,000.00. Following the transaction, the director directly owned 9,130 shares of the company's stock, valued at $540,952.50. The trade was a 30.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 66,859 shares of company stock valued at $3,687,577 over the last three months. 4.90% of the stock is currently owned by company insiders.

Protagonist Therapeutics Stock Up 4.9%

Protagonist Therapeutics stock opened at $62.14 on Friday. The firm has a 50-day moving average price of $56.37 and a two-hundred day moving average price of $51.29. The firm has a market capitalization of $3.87 billion, a price-to-earnings ratio of 88.77 and a beta of 2.22. Protagonist Therapeutics, Inc. has a 52-week low of $33.31 and a 52-week high of $62.21.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.53) by ($0.02). The firm had revenue of $5.55 million for the quarter, compared to analyst estimates of $8.32 million. Protagonist Therapeutics had a net margin of 24.88% and a return on equity of 8.12%. Research analysts expect that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current year.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.

Want to see what other hedge funds are holding PTGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.